Asked by: Roz Savage (Liberal Democrat - South Cotswolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the closure of specialist Long Covid clinics on the collection of data on the long-term health impacts of Covid-19; and what steps he is taking to ensure that these conditions are not under-recognised or under-resourced as a result.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
While no central assessment has been made of the impact of local closures of post-COVID-19 services on patient outcomes and data collection, the Government understands the scale of the issue at hand, particularly the impact of long COVID-19 on health, employment, and the economy.
The Government is aware that post-acute infection conditions, such as long COVID-19, can have a devastating effect on those who suffer from them. We are committed to taking a comprehensive and compassionate approach to supporting individuals with post-acute infection conditions such as long COVID-19, recognising the unique challenges these conditions present.
Integrated care boards are responsible for commissioning specialist services for long COVID-19 that meet the needs of their population, subject to local prioritisation and funding. NHS England has published commissioning guidance for post-COVID-19, or long COVID-19, services, which sets out a blueprint for best practice in supporting people with long COVID-19 and is designed to be adapted to local needs. This guidance is avaiable at the following link:
https://www.england.nhs.uk/publication/national-commissioning-guidance-for-post-covid-services/
Anyone who is concerned about long lasting symptoms after having COVID-19 should contact their general practitioner (GP). If appropriate, their GP will refer them to a National Health Service long COVID-19 service where available, or a suitable alternative, which will assess people and direct them into care pathways which provide appropriate support, treatment, and rehabilitation.
To support clinical leadership in this area, NHS England worked in partnership with the British Society of Physical and Rehabilitation Medicine to establish the International Post- Covid and Post-Infection Conditions Society to facilitate the ongoing sharing of best practice to support people affected by long COVID-19.
Ongoing projects funded through the National Institute of Health and Care Research (NIHR) and Medical Research Council (MRC) aim to improve our understanding of the diagnosis and underlying mechanisms of long COVID-19 and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate clinical care. The NIHR welcomes funding applications for research into any aspect of human health, including long COVID-19. The NIHR and MRC remain committed to funding high-quality research to understand the causes, consequences, and treatment of post-viral conditions, including long COVID-19, and are actively exploring next steps for research into post-viral conditions.
On 6 November 2025, the NIHR and MRC hosted a showcase event for post-acute infection conditions, including long COVID-19, research. This brought together people with lived experience, researchers, clinicians, and research funders to help stimulate further research in this field. We are now considering discussions from the showcase event to explore next steps to stimulate further vital research in this area.
We are determined to accelerate progress in the treatment and management of long COVID-19. This includes a new funding opportunity for a development award which is focussed on the feasibility of a phase 2 platform clinical trial that tests multiple repurposed pharmaceutical interventions and/or non-pharmacological interventions and devices. This targeted funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including long COVID-19.
Asked by: Roz Savage (Liberal Democrat - South Cotswolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the closure of dedicated Long Covid services on patient outcomes; and what steps he is taking to ensure that the long-term effects of Covid-19 are (a) properly identified, (b) monitored and (c) treated.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
While no central assessment has been made of the impact of local closures of post-COVID-19 services on patient outcomes and data collection, the Government understands the scale of the issue at hand, particularly the impact of long COVID-19 on health, employment, and the economy.
The Government is aware that post-acute infection conditions, such as long COVID-19, can have a devastating effect on those who suffer from them. We are committed to taking a comprehensive and compassionate approach to supporting individuals with post-acute infection conditions such as long COVID-19, recognising the unique challenges these conditions present.
Integrated care boards are responsible for commissioning specialist services for long COVID-19 that meet the needs of their population, subject to local prioritisation and funding. NHS England has published commissioning guidance for post-COVID-19, or long COVID-19, services, which sets out a blueprint for best practice in supporting people with long COVID-19 and is designed to be adapted to local needs. This guidance is avaiable at the following link:
https://www.england.nhs.uk/publication/national-commissioning-guidance-for-post-covid-services/
Anyone who is concerned about long lasting symptoms after having COVID-19 should contact their general practitioner (GP). If appropriate, their GP will refer them to a National Health Service long COVID-19 service where available, or a suitable alternative, which will assess people and direct them into care pathways which provide appropriate support, treatment, and rehabilitation.
To support clinical leadership in this area, NHS England worked in partnership with the British Society of Physical and Rehabilitation Medicine to establish the International Post- Covid and Post-Infection Conditions Society to facilitate the ongoing sharing of best practice to support people affected by long COVID-19.
Ongoing projects funded through the National Institute of Health and Care Research (NIHR) and Medical Research Council (MRC) aim to improve our understanding of the diagnosis and underlying mechanisms of long COVID-19 and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate clinical care. The NIHR welcomes funding applications for research into any aspect of human health, including long COVID-19. The NIHR and MRC remain committed to funding high-quality research to understand the causes, consequences, and treatment of post-viral conditions, including long COVID-19, and are actively exploring next steps for research into post-viral conditions.
On 6 November 2025, the NIHR and MRC hosted a showcase event for post-acute infection conditions, including long COVID-19, research. This brought together people with lived experience, researchers, clinicians, and research funders to help stimulate further research in this field. We are now considering discussions from the showcase event to explore next steps to stimulate further vital research in this area.
We are determined to accelerate progress in the treatment and management of long COVID-19. This includes a new funding opportunity for a development award which is focussed on the feasibility of a phase 2 platform clinical trial that tests multiple repurposed pharmaceutical interventions and/or non-pharmacological interventions and devices. This targeted funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including long COVID-19.
Asked by: Roz Savage (Liberal Democrat - South Cotswolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what data his Department holds on patient outcomes for those with Long-Covid following the closure of dedicated services; and how many former Long Covid patients are being supported through ME/CFS services.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
While no central assessment has been made of the impact of local closures of post-COVID-19 services on patient outcomes and data collection, the Government understands the scale of the issue at hand, particularly the impact of long COVID-19 on health, employment, and the economy.
The Government is aware that post-acute infection conditions, such as long COVID-19, can have a devastating effect on those who suffer from them. We are committed to taking a comprehensive and compassionate approach to supporting individuals with post-acute infection conditions such as long COVID-19, recognising the unique challenges these conditions present.
Integrated care boards are responsible for commissioning specialist services for long COVID-19 that meet the needs of their population, subject to local prioritisation and funding. NHS England has published commissioning guidance for post-COVID-19, or long COVID-19, services, which sets out a blueprint for best practice in supporting people with long COVID-19 and is designed to be adapted to local needs. This guidance is avaiable at the following link:
https://www.england.nhs.uk/publication/national-commissioning-guidance-for-post-covid-services/
Anyone who is concerned about long lasting symptoms after having COVID-19 should contact their general practitioner (GP). If appropriate, their GP will refer them to a National Health Service long COVID-19 service where available, or a suitable alternative, which will assess people and direct them into care pathways which provide appropriate support, treatment, and rehabilitation.
To support clinical leadership in this area, NHS England worked in partnership with the British Society of Physical and Rehabilitation Medicine to establish the International Post- Covid and Post-Infection Conditions Society to facilitate the ongoing sharing of best practice to support people affected by long COVID-19.
Ongoing projects funded through the National Institute of Health and Care Research (NIHR) and Medical Research Council (MRC) aim to improve our understanding of the diagnosis and underlying mechanisms of long COVID-19 and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate clinical care. The NIHR welcomes funding applications for research into any aspect of human health, including long COVID-19. The NIHR and MRC remain committed to funding high-quality research to understand the causes, consequences, and treatment of post-viral conditions, including long COVID-19, and are actively exploring next steps for research into post-viral conditions.
On 6 November 2025, the NIHR and MRC hosted a showcase event for post-acute infection conditions, including long COVID-19, research. This brought together people with lived experience, researchers, clinicians, and research funders to help stimulate further research in this field. We are now considering discussions from the showcase event to explore next steps to stimulate further vital research in this area.
We are determined to accelerate progress in the treatment and management of long COVID-19. This includes a new funding opportunity for a development award which is focussed on the feasibility of a phase 2 platform clinical trial that tests multiple repurposed pharmaceutical interventions and/or non-pharmacological interventions and devices. This targeted funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including long COVID-19.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to expand access to drug checking services, naloxone, and other overdose prevention measures.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Every drug-related death is a tragedy, and the Government is taking a public health approach to prevent these deaths and reduce harms from drugs.
Expanding access to naloxone, a life-saving overdose medication, has never been more important. In addition to the changes made in 2024 to expand access, we recently launched a ten-week United Kingdom-wide public consultation on further legislative options to expand access to take-home and emergency use naloxone.
The Government facilitates Drug Checking Facilities provided that the possession and supply of controlled drugs are licensed by the Home Office, or exceptionally, relevant exemptions under the Misuse of Drugs Regulations 2001 may apply. Drug Checking Facilities must not condone drug use and should only be delivered where licensed and operated responsibly in line with Government policy to ensure that they discourage drug use and signpost potential users to treatment and support.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of self-sampling on reaching under-screened populations for cervical cancer; and what estimate he has made of the uptake of (a) in-clinic and (b) at-home self-sampling options.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan for England: Fit for the Future, restates the National Health Service’s aim to eliminate cervical cancer by 2040 through improved uptake of cervical screening and human papillomavirus (HPV) vaccination. Delivering the plan and making progress towards committed targets is a key priority for NHS England, working with the Department, providers, and wider health system partners.
As part of this, NHS England is transforming its approach to cervical screening for under-screened women. From early 2026, they will be offered a home testing kit, starting with those who are the most overdue for screening. This will help tackle deeply entrenched barriers that keep some away from life-saving screening.
National and international evidence suggests that offering the option of HPV self-testing in under-screened groups could help overcome some of the barriers to taking part in cervical screening, leading to improved participation, and ultimately preventing more cervical cancers and associated deaths.
The equality impact assessment on the introduction of human papilloma virus (HPV) self-sampling for the under-screened population in the NHS Cervical Screening Programme can be accessed at the following link:
https://www.gov.uk/government/publications/cervical-screening-hpv-self-sampling-impact-assessments
The self-testing kits, which detect HPV, allow people to carry out this testing in the privacy and convenience of their own homes.
Self-testing specifically targets those groups consistently missing vital appointments, with younger people, ethnic minority communities facing cultural hurdles, people with a disability, and LGBT+ people all set to benefit. Those who are HPV positive on their self-test will need to be followed up with a clinician for a cervical screening test, so it is acknowledged that not all barriers to attendance will be removed with the implementation of self-testing.
Therefore, it is anticipated that there will be an increase in participation from groups that are under screened. NHS England will monitor and evaluate the impact of this programme.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will publish a delivery plan that includes (a) who is responsible for each of the actions in the Cervical cancer elimination by 2040 – plan for England, (b) when they will be delivered and (c) what the metrics are for determining the effectiveness of the programme.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan for England: Fit for the Future restates the National Health Service’s aim to eliminate cervical cancer by 2040 through improved uptake of cervical screening and human papillomavirus (HPV) vaccination. Delivering the plan and making progress towards committed targets is a key priority for NHS England, working with the Department, providers, and wider health system partners.
NHS England will be monitoring and evaluating the success of all the individual activities included with its elimination plan and new initiatives as they are developed and implemented. In addition, the World Health Organisation’s cervical cancer elimination targets will be used as the basis for ongoing monitoring, along with regular assessment of cervical cancer rates.
Achieving cervical cancer elimination is a long-term goal that depends on joined up delivery of HPV vaccination and cervical screening programmes at national, regional, and integrated care board (ICB) level.
ICBs are well placed to understand the needs of their local populations and work with partners to offer services that meet those needs. They are best positioned to plan vaccination and screening services, using the recommendations set out in the cervical cancer elimination plan.
Asked by: Nigel Huddleston (Conservative - Droitwich and Evesham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with Dairy UK and other trade bodies on the potential impact of the revised Nutrient Profiling Model (NPM) for the dairy supply chain.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in our 10-Year Health Plan for England: fit for the future, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever.
As part of this, we are committed to updating the standards which underpin the advertising restrictions on television and online and the promotion restrictions in stores and their equivalent places online on ‘less healthy’ food and drink products. The Nutrient Profiling Model (NPM) 2004/05 is plainly out of date and updating the standards will strengthen the restrictions by reflecting the latest dietary advice and more effectively target the products of most concern to childhood obesity.
The Government has met with a range of stakeholders over the past year to listen to their concerns, and officials met with Dairy UK in August 2025.
The Government remains committed to engaging relevant stakeholders and we will consult this year on the application of an updated NPM’s to the advertising and promotion restrictions to ensure they can feed in their views.
Asked by: Andrew Rosindell (Reform UK - Romford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce instances of type 2 diabetes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to tackling preventable ill health, such as type 2 diabetes, head-on and at the earliest opportunity. Excess weight and obesity are key risk factors for type 2 diabetes and we are taking decisive action on the obesity crisis, easing the strain on the National Health Service and creating the healthiest generation of children ever.
We have delivered on our commitment to restrict junk food advertising on television and online and are delivering a ban on the sale of high-caffeine energy drinks to under 16 year olds. We are limiting volume price promotions such as “buy one get one free” on less healthy food and drink and have put in place a nationally standardised Behavioural Support for Obesity Prescribing service to ensure weight loss medicines are delivered safely and effectively. We will also double the number of patients able to access the NHS Digital Weight Management programme.
In addition, we continue to support the Healthier You NHS Diabetes Prevention Programme (NHS DPP), which has offered support to over 2.4 million people who are at risk of type 2 diabetes since its establishment in 2016. The NHS DPP is highly effective and has been found to reduce attendee’s risk of developing type 2 diabetes by 37% compared to those who did not attend.
We continue to deliver the NHS Health Check, a core component of England’s cardiovascular disease prevention programme, which aims to detect those at risk of heart disease, stroke, type 2 diabetes, and kidney disease aged between 40 and 74 years old.
Asked by: Andrew Rosindell (Reform UK - Romford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make it his Department’s policy to introduce mandatory NHS testing for paediatric type 1 diabetes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing guidance and quality standards on the treatment and care of diabetes in England. The NICE guideline NG18, for type 1 and 2 diabetes, provides clinical guidelines for the diagnosis, treatment, and care of children and young people. Children with suspected type 1 diabetes should receive a blood test that checks blood glucose, or sugar, levels.
NG18 recommends that children and young people with suspected type 1 diabetes are referred immediately, on the same day, to a multidisciplinary paediatric diabetes team with the competencies needed to confirm diagnosis and provide immediate care.
NHS England has published the RightCare toolkit which supports good quality diabetes care for children and young adults and includes guidance on timely and accurate diagnosis.
Asked by: Andrew Rosindell (Reform UK - Romford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the diagnosis of type 1 diabetes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing guidance and quality standards on the treatment and care of diabetes in England. The NICE guideline NG18, for type 1 and 2 diabetes, provides clinical guidelines for the diagnosis, treatment, and care of children and young people. Children with suspected type 1 diabetes should receive a blood test that checks blood glucose, or sugar, levels.
NG18 recommends that children and young people with suspected type 1 diabetes are referred immediately, on the same day, to a multidisciplinary paediatric diabetes team with the competencies needed to confirm diagnosis and provide immediate care.
NHS England has published the RightCare toolkit which supports good quality diabetes care for children and young adults and includes guidance on timely and accurate diagnosis.